APM (Aptorum Group Ltd) Multiplikator forward rega marang pendapatan
Aptorum Group Limited (APM) minimizes biotechnological risks by developing treatments for rare pathologies and infections. This chart of the company's expected P/S ratio visualizes the dynamics of market expectations, where 5.10 represents the current level of the metric. A strong patent portfolio and surgical robotics support the quality of capital, while an academic image in oncology ensures professional trust in the brand's research.
Rincian metrik lan analitis perusahaan aptorumgroup.com (APM)
- rega pasar lan target rega analis:
- indikator valuasi pasar bisnis:
- rincian valuasi buku bisnis:
- statistik kawajiban utang lan likuiditas:
Rasio Total Utang marang Ekuitas Aptorum Group Limited|APM - Utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Aptorum Group|APM - Gunggung utang perusahaan|Utang marang nilai buku APM|APM - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Aptorum Group|Likuiditas cepet aptorumgroup.com
- data bathi bisnis lan rasio investasi:
APM - Bathi pungkasan|Bathi sing dikarepake Aptorum Group Limited|APM - Kapitalisasi marang bathi|Prakiraan rega marang bathi Aptorum Group|APM - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan APM|APM - Bathi sadurunge ngurangi bunga, pajak, penyusutan, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Aptorum Group|APM - Bathi saben saham sajroning taun lumaku|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan aptorumgroup.com|APM - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Aptorum Group Limited
- rincian pendapatan lan dodolan:
Analisis kabeh metrik perusahaan:Aptorum (APM)
It is essential for investors to determine an asset's fair value by comparing current market capitalization with projected annual revenue. By analyzing the forward P/S chart, one can assess the extent to which market expectations are overextended, which is critical for Aptorum Group Limited (APM) given its early-stage development and the high risk of failing to achieve commercial results amid a capital shortage.
Pesaing wigati
Rasio rega marang prakiraan pendapatan Haleon HLN|KVUE (Kenvue Inc) - Rega mangsa ngarep marang pendapatan|VRNA: Multiplikator forward rega marang pendapatan|Jyong Bio - Rasio rega marang pendapatan sing dikarepake|Ligand Pharmaceuticals (LGND) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep amneal.com (AMRX)|Rasio rega marang prakiraan pendapatan Perrigo|ALVO: Rega forward marang dodolan|Multiplikator forward rega marang pendapatan LQDA (Liquidia Technologies)|Multiplikator Forward P/S Galapagos Corp (GLPG)|Rasio rega marang prakiraan pendapatan ANI Pharmaceuticals ANIP|MNKD - Multiplikator forward rega marang pendapatan|AMPH: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan PCRX (Pacira Pharmaceuticals)|SPRY: Multiplikator Forward P/S|Prakiraan rega marang pendapatan Theravance Corp TBPH|Rasio rega marang prakiraan pendapatan Aquestive Therapeutics|SCPH: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Tectonic Therapeutic, Inc. (TECX)|TNXP - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|China SXT Pharmaceuticals, Inc. - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Eupraxia Pharmaceuticals, Inc. EPRX|BHST - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan EXOZ|ORMP (oramed.com) - Multiplikator forward rega marang pendapatan|Entera Bio - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan MindWalk|Rasio rega marang prakiraan pendapatan ABVC|Multiplikator Forward P/S CPIX|Rasio kapitalisasi marang dodolan sing dikarepake quantumbiopharma.com|Rasio rega marang prakiraan pendapatan FibroGen FGEN|TELO - Multiplikator forward rega marang pendapatan|Rani Therapeutics Inc - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Synergy CHC Corp SNYR|RLYB (rallybio.com) - Multiplikator forward rega marang pendapatan|LEXX: Rasio rega marang pendapatan sing dikarepake|PULM (Pulmatrix) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Pheton PTHL|Multiplikator Forward P/S LYRA|Impact BioMedical, Inc. - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S TNFA (TNF Pharmaceuticals, Inc.)|Multiplikator Forward P/S cbdMD Inc. YCBD|PRFX - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan CYTO|Lipella (LIPO) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan OptiNose Corp|Rasio rega marang prakiraan pendapatan Pieris Pharmaceuticals|procapsgroup.com - Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S PTPI|QLI (Qilian International Holding Group) - Rega forward marang dodolan|Multiplikator Forward P/S SLRN (ACELYRIN, Inc.)|Multiplikator Forward P/S TFF Pharmaceuticals, Inc TFFP
